Xuwei Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuwei Cai has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
Ya Zeng
Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publicationsJingyi Jia
Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 shared publicationsXi Su
Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
6 shared publicationsYifei Lu
Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publicationsYunfeng Wang
Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publicationsLei Zhao
Department of Radiation Oncology Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China
5 shared publications
Latest Publications
- 19 November 2026
- Published by Wiley in International Journal of Cancer
Induction Immunochemotherapy Followed by Definitive Chemoradiotherapy and Consolidation Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study
Long‐term survival after definitive concurrent chemoradiotherapy (dCCRT) remains limited in locally advanced esophageal squamous cell carcinoma (ESCC). We evaluated induction immunochemotherapy followed by dCCRT and consolidation immunotherapy in this setting. This prospective, single‐arm Phase II study enrolled 54 adults selected for definitive nonsurgical treatment. The planned regimen comprised two cycles of induction immunochemotherapy with nab‐paclitaxel, carboplatin, and a programmed cell death protein 1 (PD‐1) inhibitor, followed by dCCRT with 50.4 Gy in 28 fractions and concurrent weekly chemotherapy. The same PD‐1 inhibitor was planned as consolidation therapy for up to 1 year. The primary endpoint was the 2‐year overall survival (OS) rate. Fifty‐three patients (98.1%) completed two induction cycles, all 54 proceeded to dCCRT, and 31 (57.4%) received consolidation immunotherapy. Among all 54 enrolled patients, the 2‐year OS and progression‐free survival (PFS) rates were 84.6% (95% confidence interval [CI], 75.2%–95.0%) and 61.5% (95% CI, 49.5%–76.4%), respectively, after a median follow‐up of 28.1 months. Adverse events occurred predominantly during dCCRT and were mainly hematologic; lymphopenia and esophagitis were among the most frequent toxicities. Exploratory analyses suggested that suboptimal response after induction immunochemotherapy was associated with shorter PFS. The survival outcomes observed with this sequential approach support further evaluation of its comparative clinical benefit in randomized studies. Trial Registration: ClinicalTrials.gov (NCT05621707)
- 19 November 2026
- Published by Wiley in International Journal of Cancer
Induction Immunochemotherapy Followed by Definitive Chemoradiotherapy and Consolidation Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study
Long‐term survival after definitive concurrent chemoradiotherapy (dCCRT) remains limited in locally advanced esophageal squamous cell carcinoma (ESCC). We evaluated induction immunochemotherapy followed by dCCRT and consolidation immunotherapy in this setting. This prospective, single‐arm Phase II study enrolled 54 adults selected for definitive nonsurgical treatment. The planned regimen comprised two cycles of induction immunochemotherapy with nab‐paclitaxel, carboplatin, and a programmed cell death protein 1 (PD‐1) inhibitor, followed by dCCRT with 50.4 Gy in 28 fractions and concurrent weekly chemotherapy. The same PD‐1 inhibitor was planned as consolidation therapy for up to 1 year. The primary endpoint was the 2‐year overall survival (OS) rate. Fifty‐three patients (98.1%) completed two induction cycles, all 54 proceeded to dCCRT, and 31 (57.4%) received consolidation immunotherapy. Among all 54 enrolled patients, the 2‐year OS and progression‐free survival (PFS) rates were 84.6% (95% confidence interval [CI], 75.2%–95.0%) and 61.5% (95% CI, 49.5%–76.4%), respectively, after a median follow‐up of 28.1 months. Adverse events occurred predominantly during dCCRT and were mainly hematologic; lymphopenia and esophagitis were among the most frequent toxicities. Exploratory analyses suggested that suboptimal response after induction immunochemotherapy was associated with shorter PFS. The survival outcomes observed with this sequential approach support further evaluation of its comparative clinical benefit in randomized studies. Trial Registration: ClinicalTrials.gov (NCT05621707)
- 23 September 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-11
Real-World Analysis of Neoadjuvant Immunochemotherapy Followed by Surgery in Esophageal Cancer with Baseline Supraclavicular Lymph Node Involvement
Management of supraclavicular lymph node (SCLN) metastasis in esophageal cancer remains controversial. Neoadjuvant immunochemotherapy (nICT) may challenge
- 23 September 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-11
Real-World Analysis of Neoadjuvant Immunochemotherapy Followed by Surgery in Esophageal Cancer with Baseline Supraclavicular Lymph Node Involvement
Management of supraclavicular lymph node (SCLN) metastasis in esophageal cancer remains controversial. Neoadjuvant immunochemotherapy (nICT) may challenge
- Open Access
- 20 May 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101254
Potential benefit of postoperative radiotherapy for patients with stage III(N2) non-small cell lung cancer: a retrospective, propensity-score matched study
- 20 May 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101254
Open AccessPotential benefit of postoperative radiotherapy for patients with stage III(N2) non-small cell lung cancer: a retrospective, propensity-score matched study
- 14 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2502536
Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment
PURPOSE: The optimal second-line strategy for patients with extensive-stage small cell lung cancer (ES-SCLC) developing brain-only progression (BOP) after first-line therapy remains undefined. We aimed to evaluate the efficacy of continuing the original systemic therapy versus switching strategies. METHODS: This multicenter cohort study screened 889 patients with ES-SCLC. A total of 203 patients developing BOP were assigned to 3 second-line strategies: continuation of original systemic therapy plus brain radiotherapy (OTP + BRT), substitution therapy plus BRT (ST + BRT), or substitution therapy alone (ST). Inverse probability of treatment weighting was used to balance baseline characteristics. The primary end point was overall survival from second-line initiation (OS2). RESULTS: In the inverse probability of treatment weighting–weighted analysis of 203 BOP patients, OTP + BRT demonstrated significantly superior median OS2 (14.7 months) compared with ST (10.2 months; hazard ratio [HR], 1.68; P = .028) and ST + BRT (9.8 months; HR, 1.67; P = .023). OTP + BRT also yielded improved median second-line progression-free survival (PFS) (8.0 months) versus ST (4.0 months; P = .024). Multivariable analysis confirmed OTP + BRT as an independent prognostic factor for improved survival. The benefit was most pronounced in patients with prior immunotherapy and longer initial PFS (≥7.5 months). No significant survival differences were observed among radiotherapy modalities (whole-brain radiotherapy v stereotactic radiosurgery). CONCLUSION: For ES-SCLC patients with BOP, continuing the original systemic regimen plus BRT yields superior survival compared with switching systemic therapy. This supports a site-of-progression–directed strategy, effectively controlling the CNS sanctuary while maintaining an effective systemic backbone.
- 14 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2502536
Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment
PURPOSE: The optimal second-line strategy for patients with extensive-stage small cell lung cancer (ES-SCLC) developing brain-only progression (BOP) after first-line therapy remains undefined. We aimed to evaluate the efficacy of continuing the original systemic therapy versus switching strategies. METHODS: This multicenter cohort study screened 889 patients with ES-SCLC. A total of 203 patients developing BOP were assigned to 3 second-line strategies: continuation of original systemic therapy plus brain radiotherapy (OTP + BRT), substitution therapy plus BRT (ST + BRT), or substitution therapy alone (ST). Inverse probability of treatment weighting was used to balance baseline characteristics. The primary end point was overall survival from second-line initiation (OS2). RESULTS: In the inverse probability of treatment weighting–weighted analysis of 203 BOP patients, OTP + BRT demonstrated significantly superior median OS2 (14.7 months) compared with ST (10.2 months; hazard ratio [HR], 1.68; P = .028) and ST + BRT (9.8 months; HR, 1.67; P = .023). OTP + BRT also yielded improved median second-line progression-free survival (PFS) (8.0 months) versus ST (4.0 months; P = .024). Multivariable analysis confirmed OTP + BRT as an independent prognostic factor for improved survival. The benefit was most pronounced in patients with prior immunotherapy and longer initial PFS (≥7.5 months). No significant survival differences were observed among radiotherapy modalities (whole-brain radiotherapy v stereotactic radiosurgery). CONCLUSION: For ES-SCLC patients with BOP, continuing the original systemic regimen plus BRT yields superior survival compared with switching systemic therapy. This supports a site-of-progression–directed strategy, effectively controlling the CNS sanctuary while maintaining an effective systemic backbone.
- Open Access
- 10 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1818306
Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis
"[The one-year and two-year OS rates were 80.4% and 50.9%, respectively, in RT group, compared to 62.2% and 34.1%, respectively, in Non-RT group.]" [The PFS data after PSM was incorrectly copied as OS data]. A correction has been made to the section [Results, Survival outcomes, Paragraph 3]: "[After PSM, significant improvements in PFS(Figure3C,12.7months vs 6.5months, HR= 0.47, 95%CI:0.39-0.56, p<0.001)]" The original version of this article has been updated.
- 10 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1818306
Open AccessCorrection: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis
"[The one-year and two-year OS rates were 80.4% and 50.9%, respectively, in RT group, compared to 62.2% and 34.1%, respectively, in Non-RT group.]" [The PFS data after PSM was incorrectly copied as OS data]. A correction has been made to the section [Results, Survival outcomes, Paragraph 3]: "[After PSM, significant improvements in PFS(Figure3C,12.7months vs 6.5months, HR= 0.47, 95%CI:0.39-0.56, p<0.001)]" The original version of this article has been updated.
- Open Access
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1738352
Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis
Backgrounds: This study aimed to evaluate efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). Methods: ES-SCLC patients treated with first-line chemo-immunotherapy from August 2018 to January 2024 at five centers were included. Patients receiving early radiotherapy administered before disease progression were categorized into RT group, and were further separately stratified by the receipt of thoracic radiotherapy (TRT) and extra thoracic radiotherapy (eTRT). Propensity score matching (PSM) was performed to balance potential bias. Results: Totally, 771 patients were enrolled. RT group exhibited significantly better progression-free survival (PFS, p<0.001) and overall survival (OS, p<0.001) compared to Non-RT group in the whole and post-PSM cohort. The survival benefit was also observed in TRT group versus Non-TRT group, and eTRT group versus Non-eTRT group. Exploratory analyses were conducted within the TRT group. Consolidative TRT was associated with superior PFS (p<0.001) and OS (p=0.006) compared to the concurrent treatment. Additionally, survival outcomes were comparable between patients receiving a biological effective dose (BED) below or above the median dose of 60Gy and the salvage dose of 39Gy. No significance was observed in overall adverse events between RT group and Non-RT group, despite a higher rate of all-grade pneumonitis in RT group (9.9% versus 4.2%, p=0.002). Conclusions: Early radiotherapy, either thoracic or extra thoracic radiotherapy, combined with first-line chemo-immunotherapy constituted an effective and well-tolerated strategy for patients with ES-SCLC. These findings warrant investigation in prospective randomized trials.
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1738352
Open AccessEfficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis
Backgrounds: This study aimed to evaluate efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). Methods: ES-SCLC patients treated with first-line chemo-immunotherapy from August 2018 to January 2024 at five centers were included. Patients receiving early radiotherapy administered before disease progression were categorized into RT group, and were further separately stratified by the receipt of thoracic radiotherapy (TRT) and extra thoracic radiotherapy (eTRT). Propensity score matching (PSM) was performed to balance potential bias. Results: Totally, 771 patients were enrolled. RT group exhibited significantly better progression-free survival (PFS, p<0.001) and overall survival (OS, p<0.001) compared to Non-RT group in the whole and post-PSM cohort. The survival benefit was also observed in TRT group versus Non-TRT group, and eTRT group versus Non-eTRT group. Exploratory analyses were conducted within the TRT group. Consolidative TRT was associated with superior PFS (p<0.001) and OS (p=0.006) compared to the concurrent treatment. Additionally, survival outcomes were comparable between patients receiving a biological effective dose (BED) below or above the median dose of 60Gy and the salvage dose of 39Gy. No significance was observed in overall adverse events between RT group and Non-RT group, despite a higher rate of all-grade pneumonitis in RT group (9.9% versus 4.2%, p=0.002). Conclusions: Early radiotherapy, either thoracic or extra thoracic radiotherapy, combined with first-line chemo-immunotherapy constituted an effective and well-tolerated strategy for patients with ES-SCLC. These findings warrant investigation in prospective randomized trials.
- Open Access
- 18 November 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (22) , e70191
Neoadjuvant Chemoimmunotherapy Combined With Node‐Sparing Radiotherapy for Clinical T3N + Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Single‐Arm, Phase II Study ( CINSREC Trial)
Introduction: The promising therapeutic outcomes of neoadjuvant chemoimmunotherapy (NCIT) in locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by multiple phase II clinical trials and are widely used in clinical practice. However, there are some cases, such as clinical T3N+ stage, that achieve poor tumor regression after receiving NCIT, reflecting the insufficient efficacy of NCIT for advanced T‐type tumors. It may be necessary to add concurrent radiotherapy to further improve the local control effect of tumor, but it also means higher adverse events and immune suppression when irradiating tumor‐draining lymph nodes. Nevertheless, node‐sparing radiotherapy can enhance the effect of NCIT with fewer adverse effects, which has been applied to other solid tumors. The aim of this study was to evaluate the safety and efficacy of NCIT combined with node‐sparing radiotherapy for clinical T3N+ locally advanced ESCC (CINSREC trial). Methods: Forty eligible patients with pathologically confirmed ESCC of clinical T3N + M0 stage were allocated to receive neoadjuvant immunotherapy (tislelizumab, q3w × 2 cycles) plus chemotherapy (nad‐paclitaxel + carboplatin, q3w × 2 cycles) and node‐sparing radiotherapy (41.4 Gy/23 times) treatment. The primary end point of this study is the pathological complete response rate. The secondary end points include major pathological response rate, adverse events, 2‐year overall survival, and disease‐free survival. Discussion: This is the first prospective clinical trial to investigate the safety and efficacy of NCIT combined with node‐sparing radiotherapy for clinical T3N+ locally advanced ESCC. We hypothesize that this promising strategy can provide a better pCR rate and acceptable safety. Trial Registration: ClinicalTrial.gov: NCT06965829
- 18 November 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (22) , e70191
Open AccessNeoadjuvant Chemoimmunotherapy Combined With Node‐Sparing Radiotherapy for Clinical T3N + Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Single‐Arm, Phase II Study ( CINSREC Trial)
Introduction: The promising therapeutic outcomes of neoadjuvant chemoimmunotherapy (NCIT) in locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by multiple phase II clinical trials and are widely used in clinical practice. However, there are some cases, such as clinical T3N+ stage, that achieve poor tumor regression after receiving NCIT, reflecting the insufficient efficacy of NCIT for advanced T‐type tumors. It may be necessary to add concurrent radiotherapy to further improve the local control effect of tumor, but it also means higher adverse events and immune suppression when irradiating tumor‐draining lymph nodes. Nevertheless, node‐sparing radiotherapy can enhance the effect of NCIT with fewer adverse effects, which has been applied to other solid tumors. The aim of this study was to evaluate the safety and efficacy of NCIT combined with node‐sparing radiotherapy for clinical T3N+ locally advanced ESCC (CINSREC trial). Methods: Forty eligible patients with pathologically confirmed ESCC of clinical T3N + M0 stage were allocated to receive neoadjuvant immunotherapy (tislelizumab, q3w × 2 cycles) plus chemotherapy (nad‐paclitaxel + carboplatin, q3w × 2 cycles) and node‐sparing radiotherapy (41.4 Gy/23 times) treatment. The primary end point of this study is the pathological complete response rate. The secondary end points include major pathological response rate, adverse events, 2‐year overall survival, and disease‐free survival. Discussion: This is the first prospective clinical trial to investigate the safety and efficacy of NCIT combined with node‐sparing radiotherapy for clinical T3N+ locally advanced ESCC. We hypothesize that this promising strategy can provide a better pCR rate and acceptable safety. Trial Registration: ClinicalTrial.gov: NCT06965829
- Open Access
- 6 June 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-10
Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy
This real-world study aimed to investigate the efficacy of early radiotherapy (RT) in ES-SCLC patients treated with first-line chemo-immunotherapy. ES-SCLC patients were enrolled from August 2018 to October 2023. Patients who received early radiotherapy before disease progression were defined as Early RT group, while the others, named Salvage and Non-RT (S&N RT) group. Propensity score matching (PSM) with a 1:1 ratio was performed to balance the baseline characteristics. In this study, 375 patients with ES-SCLC treated with first-line chemo-immunotherapy were enrolled. The median PFS was 11.4 months of the Early RT group compared to 6.1 months of the S&N RT group (HR = 0.59, 95%CI 0.45–0.77; p < 0.001). The median OS was 23.8 months of the Early RT group versus 18.0 months of the S&N RT group (HR = 0.50, 95%CI 0.34–0.73; p = 0.004). The survival benefit persisted in the PSM cohort. Furthermore, survival was significantly improved in Early RT group compared to Salvage RT group (p = 0.028), while Salvage RT group had a similar survival with Non-RT group (p = 0.868). The risk of adverse events was tolerable. The multivariate analysis also demonstrated that early radiotherapy was an independently positive predictor for PFS and OS. Administering early radiotherapy significantly improved both PFS and OS in patients with ES-SCLC treated with first-line chemo-immunotherapy with tolerable adverse events, while salvage radiotherapy did not improve survival. This finding warrants further validation through prospective randomized studies.
- 6 June 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-10
Open AccessEarly radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy
This real-world study aimed to investigate the efficacy of early radiotherapy (RT) in ES-SCLC patients treated with first-line chemo-immunotherapy. ES-SCLC patients were enrolled from August 2018 to October 2023. Patients who received early radiotherapy before disease progression were defined as Early RT group, while the others, named Salvage and Non-RT (S&N RT) group. Propensity score matching (PSM) with a 1:1 ratio was performed to balance the baseline characteristics. In this study, 375 patients with ES-SCLC treated with first-line chemo-immunotherapy were enrolled. The median PFS was 11.4 months of the Early RT group compared to 6.1 months of the S&N RT group (HR = 0.59, 95%CI 0.45–0.77; p < 0.001). The median OS was 23.8 months of the Early RT group versus 18.0 months of the S&N RT group (HR = 0.50, 95%CI 0.34–0.73; p = 0.004). The survival benefit persisted in the PSM cohort. Furthermore, survival was significantly improved in Early RT group compared to Salvage RT group (p = 0.028), while Salvage RT group had a similar survival with Non-RT group (p = 0.868). The risk of adverse events was tolerable. The multivariate analysis also demonstrated that early radiotherapy was an independently positive predictor for PFS and OS. Administering early radiotherapy significantly improved both PFS and OS in patients with ES-SCLC treated with first-line chemo-immunotherapy with tolerable adverse events, while salvage radiotherapy did not improve survival. This finding warrants further validation through prospective randomized studies.
- Open Access
- 18 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy
The therapeutic advantage of radiotherapy (RT) as an adjunct to first-line immunotherapy and chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) remains unclear. This study aimed to elucidate the value of RT based on the first failure pattern of ES-SCLC. In this study, we retrospectively analyzed ES-SCLC patients treated with first-line chemotherapy and immune checkpoint inhibitors (ICIs) at Shanghai Chest Hospital from August 2018 to October 2023. Our study recorded the first failure pattern in ES-SCLC, analyzed the main sites of disease progression, explored factors that may affect prognosis and estimated the value of RT in extending patient survival in the immunotherapy era. Key endpoints included the first failure pattern, progression-free survival (PFS) and overall survival (OS). Among 344 patients, 70 (20%) had local failure, 105 (31%) had distant failure, 69 (20%) experienced both types of failure, and 100 (29%) showed no disease progression. Disease progression occurred in 244 patients (71%). They were divided into two groups: 183 without pre-progression RT and 61 with pre-progression RT. In the non-pre-progression RT group, 55 patients (30%) had local failure, 72 patients (39%) had distant failure, and 56 patients (31%) had both. In the pre-progression RT group, 15 patients (25%) had local failure, 33 patients (54%) had distant failure, and 13 patients (21%) had both. Univariate and multivariate analyses identified RT as an independent prognostic factor for improved OS (P < 0.05). Subgroup analysis further confirmed these findings. Pre-progression RT was associated with superior PFS (P < 0.05). The median overall survival (mOS) was 20.1 months (95% confidence interval [CI]: 15.5–24.7 months) in the pre-progression RT group, compared to 13.4 months (95% CI: 13.4–19.2 months) in the non-pre-progression RT group. RT improved OS in these patients, and pre-progression RT improved PFS further. Pre-progression RT shows a trend toward OS benefit.
- 18 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Open AccessThe role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy
The therapeutic advantage of radiotherapy (RT) as an adjunct to first-line immunotherapy and chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) remains unclear. This study aimed to elucidate the value of RT based on the first failure pattern of ES-SCLC. In this study, we retrospectively analyzed ES-SCLC patients treated with first-line chemotherapy and immune checkpoint inhibitors (ICIs) at Shanghai Chest Hospital from August 2018 to October 2023. Our study recorded the first failure pattern in ES-SCLC, analyzed the main sites of disease progression, explored factors that may affect prognosis and estimated the value of RT in extending patient survival in the immunotherapy era. Key endpoints included the first failure pattern, progression-free survival (PFS) and overall survival (OS). Among 344 patients, 70 (20%) had local failure, 105 (31%) had distant failure, 69 (20%) experienced both types of failure, and 100 (29%) showed no disease progression. Disease progression occurred in 244 patients (71%). They were divided into two groups: 183 without pre-progression RT and 61 with pre-progression RT. In the non-pre-progression RT group, 55 patients (30%) had local failure, 72 patients (39%) had distant failure, and 56 patients (31%) had both. In the pre-progression RT group, 15 patients (25%) had local failure, 33 patients (54%) had distant failure, and 13 patients (21%) had both. Univariate and multivariate analyses identified RT as an independent prognostic factor for improved OS (P < 0.05). Subgroup analysis further confirmed these findings. Pre-progression RT was associated with superior PFS (P < 0.05). The median overall survival (mOS) was 20.1 months (95% confidence interval [CI]: 15.5–24.7 months) in the pre-progression RT group, compared to 13.4 months (95% CI: 13.4–19.2 months) in the non-pre-progression RT group. RT improved OS in these patients, and pre-progression RT improved PFS further. Pre-progression RT shows a trend toward OS benefit.